|
Name |
7-epi-Brefeldin A
|
| Molecular Formula | C16H24O4 | |
| IUPAC Name* |
(1R,2R,3E,7S,11E,13S,15R)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one
|
|
| SMILES |
C[C@H]1CCC/C=C/[C@@H]2C[C@H](C[C@H]2[C@@H](/C=C/C(=O)O1)O)O
|
|
| InChI |
InChI=1S/C16H24O4/c1-11-5-3-2-4-6-12-9-13(17)10-14(12)15(18)7-8-16(19)20-11/h4,6-8,11-15,17-18H,2-3,5,9-10H2,1H3/b6-4+,8-7+/t11-,12+,13+,14+,15+/m0/s1
|
|
| InChIKey |
KQNZDYYTLMIZCT-MBKTUJMASA-N
|
|
| Synonyms |
7-epi-Brefeldin; 7-epi-Brefeldin A; S66RHK02RP; NSC-372200; (1R,2E,6S,10E,11aS,13R,14aR)-1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent(f)oxacyclotridecin-4-one; 4H-Cyclopent(f)oxacyclotridecin-4-one, 1,6,7,8,9,11a,12,13,14,14a-decahydro-1,13-dihydroxy-6-methyl-, (1R,2E,6S,10E,11aS,13R,14aR)-; 83710-00-3; UNII-S66RHK02RP
|
|
| CAS | 83710-00-3 | |
| PubChem CID | 12302047 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 280.36 | ALogp: | 2.0 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
| Heavy Atoms: | 20 | QED Weighted: | 0.529 |
| Caco-2 Permeability: | -4.685 | MDCK Permeability: | 0.00014190 |
| Pgp-inhibitor: | 0.38 | Pgp-substrate: | 0.537 |
| Human Intestinal Absorption (HIA): | 0.028 | 20% Bioavailability (F20%): | 0.056 |
| 30% Bioavailability (F30%): | 0.963 |
| Blood-Brain-Barrier Penetration (BBB): | 0.982 | Plasma Protein Binding (PPB): | 78.34% |
| Volume Distribution (VD): | 0.431 | Fu: | 13.18% |
| CYP1A2-inhibitor: | 0.028 | CYP1A2-substrate: | 0.108 |
| CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.248 |
| CYP2C9-inhibitor: | 0.047 | CYP2C9-substrate: | 0.875 |
| CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.446 |
| CYP3A4-inhibitor: | 0.491 | CYP3A4-substrate: | 0.239 |
| Clearance (CL): | 7.84 | Half-life (T1/2): | 0.878 |
| hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.899 |
| Drug-inuced Liver Injury (DILI): | 0.429 | AMES Toxicity: | 0.023 |
| Rat Oral Acute Toxicity: | 0.831 | Maximum Recommended Daily Dose: | 0.962 |
| Skin Sensitization: | 0.833 | Carcinogencity: | 0.879 |
| Eye Corrosion: | 0.515 | Eye Irritation: | 0.476 |
| Respiratory Toxicity: | 0.323 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003784 | ![]() |
1.000 | D02FEM | ![]() |
0.248 | ||
| ENC005098 | ![]() |
1.000 | D0Z1FX | ![]() |
0.237 | ||
| ENC003460 | ![]() |
1.000 | D08PIQ | ![]() |
0.229 | ||
| ENC004599 | ![]() |
0.697 | D06WTZ | ![]() |
0.225 | ||
| ENC004602 | ![]() |
0.697 | D0H0ND | ![]() |
0.221 | ||
| ENC004603 | ![]() |
0.676 | D0WE3O | ![]() |
0.221 | ||
| ENC001860 | ![]() |
0.672 | D0CZ1Q | ![]() |
0.217 | ||
| ENC001867 | ![]() |
0.627 | D0V9DZ | ![]() |
0.217 | ||
| ENC003403 | ![]() |
0.627 | D0D2TN | ![]() |
0.217 | ||
| ENC005407 | ![]() |
0.559 | D03IKT | ![]() |
0.213 | ||